---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-24-000092"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2024-05-24T23:59:59+00:00"
generated_at: "2026-06-01T08:43:17.609337+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Summit partner Akeso wins China NMPA approval for ivonescimab in EGFR-mutated NSCLC

## Summary
- NMPA approved ivonescimab + chemo for EGFR-mutated advanced non-squamous NSCLC after TKI failure.
- First regulatory approval for ivonescimab globally; based on HARMONi-A Phase III trial.
- Median PFS by IRRC: 7.06 mo (ivonescimab) vs 4.80 mo (chemo alone); HR 0.46 (95% CI 0.34-0.62).
- Grade ≥3 TEAEs: 61.5% in ivonescimab arm vs 49.1% in chemo arm; mostly chemo-related.
- Approval does not affect Summit's US/global development plan; HARMONi and HARMONi-3 trials continue.

## SEC filing metadata
- accession: 0001599298-24-000092
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2024-05-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929824000092/0001599298-24-000092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929824000092/smmt-20240524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-24-000092
- JSON: https://secwatch.observer/filing/0001599298-24-000092.json
- Plain text: https://secwatch.observer/filing/0001599298-24-000092.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.